[A24-48] Letermovir (prophylaxis of CMV reactivation and disease after stem cell transplantation) - Addendum to Project A23-139
Last updated 06.06.2024
Project no.:
A24-48
Commission:
Commission awarded on 23.04.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Immune system and infections
Prophylaxis of CMV reactivation and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant.
Unchanged after addendum:
hint of non-quantifiable added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A24-48_en
| Project no. | Title | Status |
|---|---|---|
| A23-139 | Letermovir (CMV prophylaxis after stem cell transplantation) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2024-06-06 A G-BA decision was published.